In head-to-head trial, two biologics differ markedly for control of psoriasisFebruary 4, 2021Psoriatic Arthritis
Guselkumab maintains psoriasis efficacy long after discontinuationJanuary 26, 2021Psoriatic Arthritis
Deucravacitinib offers biologic-like psoriasis efficacy in oral formJanuary 8, 2021Psoriatic Arthritis
EULAR recommendations define strategies to improve adherence in RMDsJanuary 4, 2021Psoriatic Arthritis
Synovial, skin gene expression differences may explain PsA treatment responsesDecember 11, 2020Psoriatic Arthritis
International expert group agrees on redefining psoriasis severity December 1, 2020Psoriatic Arthritis
The case for anti–IL-17 agents as first-line biologics in psoriatic arthritisNovember 30, 2020Psoriatic Arthritis
TNF inhibitor–induced psoriasis treatment algorithm maintains TNF inhibitor if possibleNovember 25, 2020Psoriatic Arthritis
